Results 81 to 90 of about 48,983 (212)

Maternal and perinatal outcomes of sickle cell disease in pregnancy: A nationwide study in France

British Journal of Haematology, Volume 206, Issue 4, Page 1218-1227, April 2025.
Summary This nationwide cohort study provides a comprehensive overview of maternal and perinatal outcomes associated with sickle cell disease (SCD) during pregnancy. Using the French national health database, all singleton pregnancy‐related hospital discharges from 2013 to 2020 in women aged 15–55 (n = 5 752 080) were selected.
Alice Corsia, Laure Joseph, Nathanael Beeker, Sandra Manceau, Marine Driessen, Benoit Meunier, Marina Cavazzana, Mathis Collier, Jean‐Marc Treluyer   +8 more
wiley   +1 more source

Pre‐symptomatic risdiplam treatment for spinal muscular atrophy initiated at 12 days post‐birth: 14‐month safety and developmental outcomes

Pediatric Investigation, EarlyView.
Zhihao Sun, Liping Wu, Yufan Hui, Yuhang Zhong, Jiangtao Yang, Zhiyong Sun, Xiaoling Huang, Hui Xiong   +7 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors

Diabetes, Obesity and Metabolism, EarlyView.
Abstract The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors represents a major turning point in the effort to preserve kidney function and prevent cardiovascular events and heart failure hospitalisations in those at high risk. These agents have now transcended their original glucose‐lowering indication and provide a range of clinical
Daniel Vincent O'Hara, Meg J. Jardine
wiley   +1 more source

Terminology Extraction for and from Communications in Multi-disciplinary Domains [PDF]

, 2016
Terminology extraction generally refers to methods and systems for identifying term candidates in a uni-disciplinary and uni-lingual environment such as engineering, medical, physical and geological sciences, or administration, business and leisure ...
Ahmad, Khurshid, Musacchio, MARIA TERESA, Panizzon, Raffaella, Zhang, Xiubo   +3 more
core  

Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To describe temporal changes in the characteristics of medication‐initiator cohorts in persons with chronic kidney disease (CKD) and type 2 diabetes (T2D). Materials and Methods Adults with CKD and T2D initiating sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) or glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) were identified in ...
Yuichiro Yano, Suguru Okami, Hiroshi Kanegae, Nikolaus G. Oberprieler, Catherine Johannes, Satoshi Yamashita, Kanae Yoshikawa‐Ryan, Csaba P. Kovesdy, David Vizcaya, Naoki Kashihara   +9 more
wiley   +1 more source

Anti‐neutrophil cytoplasmic antibodies associated interstitial pneumonia: A possible new clinical entity

European Journal of Clinical Investigation, EarlyView.
In a study of 101 idiopathic interstitial pneumonia (IIP) and interstitial pneumonia with autoimmune features (IPAF) patients, 21 (20.8%) were ANCA‐positive. ANCA+ patients had higher rates of NSIP, bronchiectasis, arthralgias, and elevated CRP, with 43% of p‐ANCA+ patients progressing to systemic vasculitis (SV) within 12 months (OR 26.3, p < .0001 ...
Claudia Iannone, Maria Rosa Pellico, Antonella Caminati, Maurizio Zompatori, Lisa Tescaro, Francesca Luisi, Davide Elia, Maria Rosa Mirenda, Matteo Colleoni, Roberto Cassandro, Sergio Harari, Roberto Felice Caporali   +11 more
wiley   +1 more source

Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update

Haemophilia, Volume 31, Issue 2, Page 247-262, March 2025.
ABSTRACT Background Von Willebrand disease (VWD) is an inherited bleeding disorder caused by deficient or dysfunctional von Willebrand factor (VWF). VWF replacement therapy is indicated in VWD management. Methods This systematic review was conducted to evaluate all available evidence of the efficacy, safety, dosing and consumption of pasteurized plasma‐
Carmen Escuriola Ettingshausen, Riitta Lassila, Gines Escolar, Christoph Male, Kathrin Schirner, Lisa Heyder, Erik Berntorp   +6 more
wiley   +1 more source

Milk and plasma pharmacokinetics of single‐dose ubrogepant in healthy lactating women

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objectives of this study were to evaluate the safety, plasma and milk pharmacokinetics, excretion in breast milk, and the relative infant dose of ubrogepant following a single oral dose. Background Ubrogepant is a calcitonin gene‐related peptide receptor antagonist approved for the acute treatment of migraine in adults ...
Ramesh R. Boinpally, Jonathan H. Smith, Eric Cohen, Joel M. Trugman   +3 more
wiley   +1 more source

Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate the postmarketing safety of monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide pathway used for migraine prophylaxis through pharmacovigilance data analysis by examining suspected adverse events reported in Europe.
Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola   +3 more
wiley   +1 more source